GlassScriptPhysician profile
Abdulkader Dahhan
NPI 1639134794
$875.01
in general payments reported to CMS, 2019-2025
18 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $42.78 · 2021: $91.52 · 2022: $65.35 · 2023: $130 · 2024: $118 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422 · Consulting Fee: $14.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.32 |
| Consulting Fee | $14.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $181.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $104.47 | 2022-2025 | Nucala, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $83.68 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $73.61 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $70.72 | 2022-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $58.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.70 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.71 | 2025 | Caplyta |
| Pfizer INC. | $29.88 | 2024-2025 | |
| Adma Biomanufacturing LLC | $28.04 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $26.60 | 2023 | Rexulti |
| Lilly USA, LLC | $24.41 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $20.14 | 2025 | |
| Smith+Nephew, INC. | $16.41 | 2024 | Collagenase Santyl |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.89 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.76 | 2021 | |
| Genentech USA, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulkader Dahhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.